POSEIDA THERAPEUTICS, INC.

Analyst Reco. Poseida Therapeutics, Inc.

Equities

PSTX

US73730P1084

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
2.13 ^USD	+3.90%		+5.45%	-36.61%

Apr. 08	Poseida Therapeutics, Inc. Presents New Phase 1 Data at AACR 2024 Supporting Potential of P-BCMA-Allo1 Allogeneic CAR-T Therapy to Benefit Broad Range of Patients with Multiple Myeloma	CI
Mar. 25	Poseida Therapeutics Appoints Syed Rizvi as Chief Medical Officer	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Piper Sandler Adjusts Price Target on Poseida Therapeutics to $10 From $8, Maintains Overweight Rating	Dec. 11	MT
HC Wainwright Adjusts Price Target on Poseida Therapeutics to $20 From $15, Keeps Buy Rating	Dec. 11	MT
HC Wainwright Initiates Poseida Therapeutics With Buy and $15 Price Target	23-01-04	MT
Piper Sandler Adjusts Price Target on Poseida Therapeutics to $11 From $9, Reiterates Overweight Rating	22-08-09	MT
Piper Sandler Adjusts Price Target on Poseida Therapeutics to $9 From $19, Maintains Overweight Rating	22-05-13	MT
Cantor Fitzgerald Starts Poseida Therapeutics at Overweight with $24 Price Target	22-01-07	MT
POSEIDA THERAPEUTICS : Piper Sandler Adjusts Poseida Therapeutics PT to $19 From $17, Maintains Overweight Rating	21-10-12	MT
POSEIDA THERAPEUTICS : BTIG Initiates Poseida Therapeutics at Buy Rating With $40 Price Target	21-05-18	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Secure and Increase the Performance of your Investments with our Team of Experts at your Side

Securing my Investments

fermer